Japan Antiphospholipid syndrome-Stroke Prevention Study

UMIN ID: C000000342

Registered date:01/03/2006

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Antiphospholipid syndrome
• Date of first enrollment: 2006/03/31
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Warfarin, INR 2.0, 2 years
cilostazol, 200mg/day, 2 years or ticlopidine, 100-200mg/day, 2 years

Outcome(s)

• Primary Outcome: Cerebral Infarct Score in MRI

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Female patients who are pregnant or plans to be pregnant Patients who cannot have warfarin or antiplatetet drugs Patients who are required to take warfarin Patients with severe hepatic, renal or cardiac failure Other inadequate patients for this clinical trial

Related Information

• Primary Sponsor: JASPRES team
• Source(s) of Monetary Support: Health and Labour Sciences Research Grants